1.P190Chronic Myeloid Leukemia Following a Course of S-1 Plus Oxaliplatin Therapy For Advanced Gastric Adenocarcinoma.
Hua WANG ; Zhi-Yong WANG ; Chun-Hong XIN ; Ying-Hui SHANG ; Rui JING ; Fa-Hong YAN ; Si-Zhou FENG
Chinese Medical Journal 2017;130(4):495-496
Adenocarcinoma
;
complications
;
drug therapy
;
metabolism
;
Aged
;
Antineoplastic Agents
;
therapeutic use
;
Fusion Proteins, bcr-abl
;
metabolism
;
Humans
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
;
diagnosis
;
etiology
;
metabolism
;
Male
;
Organoplatinum Compounds
;
therapeutic use
;
Stomach Neoplasms
;
drug therapy
;
metabolism
2.A Rare Case of Chronic Myelogenous Leukemia and Plasma Cell Myeloma in the Same Patient.
Sunhyun AHN ; Joon Seong PARK ; Jae Ho HAN ; Sung Ran CHO
Annals of Laboratory Medicine 2015;35(3):370-372
No abstract available.
Aged
;
Antineoplastic Agents/therapeutic use
;
Bone Marrow/pathology
;
Fusion Proteins, bcr-abl/genetics/metabolism
;
Humans
;
Imatinib Mesylate/therapeutic use
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications/*diagnosis/drug therapy
;
Leukocyte Count
;
Male
;
Multiple Myeloma/complications/*diagnosis/drug therapy
;
Platelet Count
;
Polymerase Chain Reaction
;
Thrombocytosis/etiology
3.Persistent suboptimal molecular response in a patient with chronic myelogenous leukemia and Klinefelter syndrome.
Rajshekhar CHAKRABORTY ; Shiva Kumar Reddy MUKKAMALLA ; Kranthi SINGAM ; Natalia CALDERON
The Korean Journal of Internal Medicine 2014;29(6):827-829
No abstract available.
Adult
;
Antineoplastic Agents/therapeutic use
;
*Chromosome Deletion
;
*Chromosomes, Human, Pair 9
;
Cytogenetic Analysis
;
DNA Mutational Analysis
;
Fusion Proteins, bcr-abl/*antagonists & inhibitors/genetics/metabolism
;
Gene Expression Regulation
;
Humans
;
Incidental Findings
;
Klinefelter Syndrome/complications/diagnosis/*genetics
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications/diagnosis/*drug therapy/enzymology/genetics
;
Male
;
Molecular Targeted Therapy
;
Protein Kinase Inhibitors/*therapeutic use
;
Remission Induction
;
Time Factors
;
Treatment Outcome
4.Ph+ acute lymphoblastic leukemia combined with lung and brain invasive aspergillosis.
Mei HUANG ; Jian-Feng ZHOU ; Dan RAN ; Yi-Cheng ZHANG ; Han-Ying SUN ; Wen-Li LIU
Journal of Experimental Hematology 2006;14(3):610-613
This study was aimed to investigate the clinical features and therapy of Ph(+) acute lymphoblastic leukemia (Ph(+)ALL) combined with invasive aspergillosis. A series of examination, including routine blood and bone marrow picture analysis, chest roentgenography, cranial computerized tomography and detection of cell genetics etc were carried out for a Ph(+)ALL patient combined with invasive aspergillosis. This patient received chemotherapy with DVCP, idarubicin and imatinib mesylate and was treated with sporanox and amphotericin B (Amb; including Amb-L) and cerebrotomy for drainage because the invasive aspergillosis occurred during myelosuppression. The results showed that patient gained complete remission and the invasive aspergillosis was controlled successfully. It is concluded that patient with Ph(+)ALL has poor prognosis despite intensive conventional chemotherapy, imatinib mesylate may prove to be an effective treatment for Ph(+)ALL. Because detection rate of the fungus is very low, itraconazole in combination with surgical excision of focus is the best treatment of lung and brain invasive aspergillosis.
Antifungal Agents
;
therapeutic use
;
Antineoplastic Combined Chemotherapy Protocols
;
therapeutic use
;
Aspergillosis
;
diagnosis
;
drug therapy
;
Benzamides
;
Brain Diseases
;
complications
;
microbiology
;
Humans
;
Imatinib Mesylate
;
Itraconazole
;
therapeutic use
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
;
complications
;
Lung Diseases, Fungal
;
drug therapy
;
etiology
;
Piperazines
;
administration & dosage
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma
;
complications
;
genetics
;
microbiology
;
Pyrimidines
;
administration & dosage